How Pharma CEOs Delegate Pricing and Market Access
Pricing and market access decisions in the pharmaceutical industry sit at the intersection of science, economics, politics, and ethics. Get them wrong and you face Congressional hearings, payer rejection, and patient access failures. Get them right and you fund the next generation of innovation while expanding reach to patients who need your products. The stakes are high enough that many pharma CEOs instinctively hold these decisions close.
That instinct creates a problem. Pricing and market access are specialized disciplines that require deep expertise in health economics, payer dynamics, reimbursement policy, and evidence strategy. The CEO brings strategic judgment and stakeholder authority. But the analytical, negotiating, and policy work that supports pricing and access decisions requires a dedicated team with capabilities that extend well beyond what any individual executive can maintain.
This article addresses how to build the right organizational structure for pricing and market access, what the CEO should retain, and how to maintain accountability without becoming a bottleneck in one of the most complex functions in your commercial organization.
Understanding the Scope of This Function
Pricing and market access in pharma encompasses several interconnected activities that are often siloed in ways that create coordination problems.
Pricing strategy. Setting launch prices, managing price changes over the product lifecycle, navigating international reference pricing, and responding to government price negotiation pressure.
Health economics and outcomes research (HEOR). Generating the economic evidence that justifies pricing to payers, HTA bodies, and clinical decision-makers. This includes cost-effectiveness models, budget impact analyses, and real-world evidence studies.
Payer strategy and contracting. Developing and negotiating rebate agreements, formulary access deals, and value-based contracts with commercial payers, pharmacy benefit managers, and government programs.
Market access execution. Operationalizing payer strategies, managing formulary positions, monitoring coverage decisions, and responding to coverage denials.
Policy and government affairs. Engaging with policy makers on pricing legislation, drug pricing reform, and Medicare/Medicaid policy changes.
Each of these is a full-time area of expertise. The CEO’s job is to build an organization that covers all of them effectively, not to personally master any of them.
What the CEO Retains
Launch Pricing Decisions
The CEO should be directly involved in launch pricing decisions for significant products, not because the CEO develops the price, but because launch pricing is a strategic decision with major commercial, reputational, and policy implications.
Your pricing and market access team, likely led by a VP or Chief Commercial Officer, will develop pricing scenarios with supporting evidence. That analysis should include market research on willingness to pay, competitive pricing benchmarks, payer landscape assessment, reimbursement probability at various price points, and international pricing implications.
The CEO reviews the analysis, stress-tests the assumptions, and makes the final call or approves the recommended price. That is a one-time, high-consequence decision that warrants CEO involvement. The months of analytical work that produce those pricing scenarios do not.
Government and Policy Engagement
In today’s environment, pharma CEOs are regularly called to engage with legislators, regulators, and policy makers on pricing and access topics. That engagement is a CEO-level responsibility. Preparing for it, including policy analysis, message development, and stakeholder mapping, is the work of your government affairs and market access teams.
Be clear about the distinction: the CEO speaks to policy makers. The team prepares the CEO to do so and manages the relationship maintenance between high-profile engagements.
Board-Level Pricing Accountability
The board expects the CEO to be able to explain and defend pricing decisions, articulate the value evidence supporting those decisions, and describe the organization’s market access strategy. That accountability cannot be delegated. But carrying it effectively does not require the CEO to manage payer contracts. It requires the CEO to maintain enough understanding of the pricing and access landscape to speak credibly to it.
Building the Right Team Structure
The Head of Pricing and Market Access
Most pharma companies of meaningful scale have a dedicated leader for pricing and market access, typically at the VP or Senior VP level. This person owns the entire function: pricing strategy, HEOR, payer relations, and market access execution. They report to the Chief Commercial Officer or, in some organizations, directly to the CEO.
This leader is the CEO’s primary counterpart for this function. They should be capable of making most pricing and access decisions independently within parameters that the CEO and CCO have approved. The escalation path to the CEO should be reserved for launch pricing, significant policy developments with enterprise-level implications, and any situation involving material reputational or political risk.
Health Economics and Outcomes Research
HEOR is a technical discipline that requires specialists with academic or near-academic training in health economics, epidemiology, and statistical modeling. The CEO does not engage with HEOR at a technical level. The CEO should understand what HEOR is trying to accomplish and should see summaries of key studies and their payer engagement implications. The analytical work is entirely the domain of your HEOR team.
Payer Relations and Contracting
Negotiating rebate agreements and formulary access deals with major payers is a senior commercial responsibility that belongs to your pricing and market access team, in coordination with legal and finance. The CEO is not at the negotiating table for individual payer contracts.
There are exceptions for truly strategic relationships, such as a novel value-based contract with a major payer or a government program that sets precedent for a therapeutic area. In those cases, CEO engagement at a relationship level may be appropriate, while the negotiating team manages the commercial details.
Government Affairs Integration
Pricing and market access intersect heavily with government affairs, particularly as drug pricing legislation continues to evolve. Your government affairs team should have strong functional integration with your pricing and market access organization. Policy changes can dramatically alter the economics of your pricing strategy, and your pricing team needs to be translating policy intelligence into commercial implications in real time.
For broader commercial function delegation, the article on pharma commercial delegation covers how to structure the commercial organization around CEO-level accountability. When pricing decisions connect to clinical trial design or labeling, the resource on pharma clinical trials addresses how development and commercial functions coordinate on evidence strategy.
Delegation by Activity Type
Value Dossier Development
Value dossiers, the core documents presenting clinical and economic evidence to payers and HTA bodies, are developed by your HEOR and market access teams. The CEO does not review the technical content of these documents. You should be aware that they exist, understand their strategic purpose, and be briefed on how key payers are responding to them.
Formulary Negotiations
Formulary negotiations with commercial payers and PBMs are managed by your market access and contracting team. These negotiations involve proprietary financial information and require ongoing relationship management that your team handles. The CEO is briefed on coverage outcomes (formulary tier achieved, step therapy requirements, prior authorization burden) because those outcomes directly affect revenue and patient access.
International Pricing Coordination
International pricing creates complex interdependencies because of reference pricing mechanisms that link prices across markets. Your international pricing team or your affiliate pricing leads manage those interdependencies under a framework established by your global pricing leadership.
The CEO is involved when there is tension between maximizing a specific market opportunity and protecting pricing architecture globally. Those decisions require CEO-level strategic judgment about how to balance short-term revenue against long-term pricing integrity. The analysis that informs those decisions belongs to the team.
Real-World Evidence Programs
Post-approval real-world evidence studies that support market access are research programs managed by your HEOR and medical affairs teams. The CEO approves the investment in these programs as part of the budget process. The scientific design and execution belong to the technical team.
Accountability Without Over-Involvement
For pricing and market access functions, build a governance rhythm that keeps you informed without pulling you into operational decisions.
Monthly commercial dashboard. Your market access lead provides a summary of formulary status by key payers, coverage trends, and any significant payer engagement developments. This is a ten-minute read, not a management meeting.
Quarterly pricing and access review. A structured review of market access performance against commercial objectives, pricing architecture integrity, HEOR progress on priority studies, and government affairs developments that affect pricing strategy. This review involves your CCO and VP of Pricing and Market Access. It produces decisions, not just updates.
Pre-launch pricing governance. For pipeline assets approaching launch, establish a formal pricing governance process that brings together HEOR evidence, payer research, competitive intelligence, and international pricing implications in a structured decision process. The CEO participates in the final decision meeting, not every working session leading up to it.
Policy monitoring. Assign your government affairs team to maintain a policy risk register that flags legislation, regulatory proposals, and judicial decisions that could affect pricing. Brief the CEO on material developments on a standing agenda item in your executive team meeting.
The Political Dimension
Drug pricing is a political issue in ways that few other business decisions are. That creates a specific CEO responsibility: managing the reputational and political dimensions of your pricing decisions in a way that your market access team cannot do alone.
The CEO may need to engage directly with patient advocacy groups, publish op-eds or letters explaining pricing rationale, or testify before legislative bodies. Those are CEO-level communications that require CEO-level preparation. But the underlying content, including the access programs, patient assistance commitments, and value evidence that support your pricing rationale, should be developed and managed by your market access and communications teams.
Your job in the political dimension is to be the authoritative, credible voice for decisions that have been made with rigor and that you can defend transparently. That requires understanding the decisions well and being prepared to speak to them. It does not require making every decision yourself.
According to a JAMA analysis of pharmaceutical pricing transparency and value, payers and policy makers increasingly expect pharma companies to demonstrate value evidence alongside pricing claims. Organizations with strong HEOR and market access capabilities are better positioned to make that case and to maintain formulary access in an increasingly challenging payer environment.
Investing in the Function
Pricing and market access is a function that many pharma companies have historically underinvested in relative to its strategic importance. A well-resourced HEOR team, experienced market access leadership, and strong payer relationships are competitive advantages that pay for themselves through better formulary positions, more favorable contracting outcomes, and stronger pricing sustainability.
The CEO’s role is to make the case for that investment and to ensure the function has the people, tools, and organizational standing to perform at the level your pipeline requires. A market access team that is scrambling to cover basics will not be able to build the differentiated capabilities that sophisticated payer and policy engagement demands.
The CEO’s Strategic Edge
The CEOs who navigate pricing and market access most effectively are those who have built genuine organizational capability in the function, established clear governance that reserves CEO attention for truly strategic decisions, and maintained enough personal understanding of the landscape to be credible in external stakeholder conversations.
They do not personally model cost-effectiveness scenarios. They understand what cost-effectiveness modeling is telling them and how to use that information in strategic conversations. They do not negotiate payer contracts. They set the commercial priorities that inform negotiating strategy and hold their teams accountable for the results.
That is the right balance: deep enough engagement to lead effectively, structured enough delegation to let experts do expert work. Build toward that balance and your pricing and market access function becomes a competitive advantage rather than a political liability.
Related Reading
For further context, explore How Pharma CEOs Delegate Business Development and Licensing and How Pharma CEOs Delegate Clinical Trial Operations.